Yong Fang

Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Jie Wang, Caicun Zhou, Wenxiu Yao et al. · The Lancet Oncology · 2022 · 395 citations

Medicine, Oncology, Pharmacology +11

Camrelizumab Plus Carboplatin and Paclitaxel as First-Line Treatment for Advanced Squamous NSCLC (CameL-Sq): A Phase 3 Trial

Shengxiang Ren, Jianhua Chen, Xingxiang Xu et al. · Journal of Thoracic Oncology · 2021 · 313 citations

Medicine, Oncology, Pharmacology +6

BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency

Chaoyang Sun, Yong Fang, Jian Chen et al. · Cancer Cell · 2018 · 302 citations · Full text

Life Sciences, Genetics, Molecular Biology +14

Sequential Therapy with PARP and WEE1 Inhibitors Minimizes Toxicity while Maintaining Efficacy

Yong Fang, Daniel J. McGrail, Chaoyang Sun et al. · Cancer Cell · 2019 · 241 citations · Full text

Medicine, Pharmacology, Chemotherapy +8

Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in <i>RAS</i> mutant cancers

Chaoyang Sun, Yong Fang, Jian Chen et al. · Science Translational Medicine · 2017 · 235 citations · Full text

Medicine, Cancer Biology, Pharmacology +16